RHS is a developer of sophisticated novel molecular tools for amplifying DNA and determining the genetic contents of a single cell.
Published clinical studies have shown that a primary reason for IVF failure is the embryo having the wrong number of chromosomes, which is known as aneuploidy. One of the most significant recent advances to improve IVF success rates has been the introduction of advanced Pre-implantation Genetic Screening (PGS), where embryos are screened to determine whether they have the correct number of chromosomes before being selected for IVF transfer.
Specifically developed to offer an integrated, easy to use and interpret, price competitive product, RHS’s EmbryoCellect™ is a Pre-implantation Genetic Screening kit designed to increase the chance of a successful IVF cycle.
RHS recently listed on the Australian Stock Exchange (ASX:RHS). Prior to its listing, the company received over $1 million in grants from both the Australian and South Australian Governments and raised $5.5 million in venture capital investment.
MedDev SA Alliance
MedDev SA is an alliance of leading South Australian based Medical Device companies. It facilitates the scale of new MedTech businesses while assisting existing organizations grow and develop globally.Read More
Flinders Fertility provides treatment to couples who are not able to conceive on their own.Read More
Biosensis specialises in antibodies and reagents for neuroscience, particularly neurotrophins and neurotrophin receptors.Read More
Reproductive Health Science (RHS) develops sophisticated novel molecular tools for amplifying DNA and determining the genetic contents of a single cell.Read More